Vasomotor Symptoms of Menopause Drug Pipeline Analysis Report 2025
Description
Vasomotor symptoms, which commonly include hot flashes and night sweats, are the most common symptoms that affect the majority of the women undergoing menopausal transition. Around 80% of menopausal women are reported to experience these symptoms, which usually persist for 7 to 10 years. Vasomotor symptoms of menopause often contribute to sleep and mood issues, that can substantially impact the quality of life. Thus, there is a growing demand for effective treatments offering more targeted relief, which is likely to boost investment and innovation in the drug pipeline.
Report Coverage
The Vasomotor Symptoms of Menopause Drug Pipeline Report by Expert Market Research gives comprehensive insights into vasomotor symptoms of menopause drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for vasomotor symptoms of menopause. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The vasomotor symptoms of menopause pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from vasomotor symptoms of menopause.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing vasomotor symptoms of menopause pipeline development activities.
Vasomotor Symptoms of Menopause Drug Pipeline Outlook
Vasomotor symptoms are the primary menopausal symptoms characterized by hot flashes and/or night sweats. These symptoms include episodes of profuse heat along with sweating and flushing, predominantly around the upper parts of the body such as the head, chest, neck, and upper back. Around 4 out of 5 menopausal women experience vasomotor symptoms. Fluctuation in the hormone level, particularly a drop in estrogen, is considered one of the main reasons responsible for vasomotor symptoms.
Hormone replacement therapy is an effective vasomotor symptoms of menopause treatment. Nonhormonal treatments such as fezolinetant (Veozah) or low-dose paroxetine (Paxil, Pexeva) are also prescribed to manage hot flashes or night sweats. Advancements in neurokinin research and the growth in clinical trial activity of investigational drugs that offer targeted relief are anticipated to positively influence the drug pipeline landscape for vasomotor symptoms of menopause in the coming years.
Vasomotor Symptoms of Menopause – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of vasomotor symptoms of menopause drug candidates based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase:
EMR’s vasomotor symptoms of menopause therapeutic assessment report covers 50+ drug analyses based on drug classes:
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
The vasomotor symptoms of menopause report cover phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials for vasomotor symptoms of menopause.
Vasomotor Symptoms of Menopause Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under vasomotor symptoms of menopause pipeline analysis include monoclonal antibodies, peptides, polymers, small molecules, and gene therapy. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for vasomotor symptoms of menopause.
Vasomotor Symptoms of Menopause Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR vasomotor symptoms of menopause drug report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in vasomotor symptoms of menopause clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for vasomotor symptoms of menopause. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of vasomotor symptoms of menopause drug candidates.
Drug: Fezolinetant
The objective of this randomized, placebo-controlled, double-blind study is to assess the long-term safety of the drug fezolinetant, a selective neurokinin-3 receptor antagonist, in around 260 Japanese women experiencing vasomotor symptoms associated with menopause. The study is conducted by Astellas Pharma Inc. and is under Phase III clinical development.
Drug: NOE-115
Noema Pharma AG is conducting a Phase II multi-center clinical trial to investigate the preliminary efficacy, safety, and tolerability of vasomotor symptoms of menopause drug candidate NOE-115, a triple reuptake inhibitor, in women suffering from the condition. The study has enrolled around 24 patients and is expected to be completed by April 2025.
Reasons To Buy This Report
The Vasomotor Symptoms of Menopause Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for vasomotor symptoms of menopause. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into vasomotor symptoms of menopause collaborations, regulatory environments, and potential growth opportunities.
Key Questions Answered in the Vasomotor Symptoms of Menopause – Pipeline Insight Report
Global Vasomotor Symptoms Treatment Market
Global Clinical Trials Market
Report Coverage
The Vasomotor Symptoms of Menopause Drug Pipeline Report by Expert Market Research gives comprehensive insights into vasomotor symptoms of menopause drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for vasomotor symptoms of menopause. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The vasomotor symptoms of menopause pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from vasomotor symptoms of menopause.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing vasomotor symptoms of menopause pipeline development activities.
Vasomotor Symptoms of Menopause Drug Pipeline Outlook
Vasomotor symptoms are the primary menopausal symptoms characterized by hot flashes and/or night sweats. These symptoms include episodes of profuse heat along with sweating and flushing, predominantly around the upper parts of the body such as the head, chest, neck, and upper back. Around 4 out of 5 menopausal women experience vasomotor symptoms. Fluctuation in the hormone level, particularly a drop in estrogen, is considered one of the main reasons responsible for vasomotor symptoms.
Hormone replacement therapy is an effective vasomotor symptoms of menopause treatment. Nonhormonal treatments such as fezolinetant (Veozah) or low-dose paroxetine (Paxil, Pexeva) are also prescribed to manage hot flashes or night sweats. Advancements in neurokinin research and the growth in clinical trial activity of investigational drugs that offer targeted relief are anticipated to positively influence the drug pipeline landscape for vasomotor symptoms of menopause in the coming years.
Vasomotor Symptoms of Menopause – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of vasomotor symptoms of menopause drug candidates based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
EMR’s vasomotor symptoms of menopause therapeutic assessment report covers 50+ drug analyses based on drug classes:
- Monoclonal Antibody
- Peptides
- Polymer
- Small Molecule
- Gene Therapy
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
- Oral
- Parenteral
- Others
The vasomotor symptoms of menopause report cover phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials for vasomotor symptoms of menopause.
Vasomotor Symptoms of Menopause Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under vasomotor symptoms of menopause pipeline analysis include monoclonal antibodies, peptides, polymers, small molecules, and gene therapy. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for vasomotor symptoms of menopause.
Vasomotor Symptoms of Menopause Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR vasomotor symptoms of menopause drug report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in vasomotor symptoms of menopause clinical trials:
- Noema Pharma AG
- Hansoh BioMedical R&D Company
- Astellas Pharma Inc.
- Bonafide Health
- Lindus Health
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for vasomotor symptoms of menopause. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of vasomotor symptoms of menopause drug candidates.
Drug: Fezolinetant
The objective of this randomized, placebo-controlled, double-blind study is to assess the long-term safety of the drug fezolinetant, a selective neurokinin-3 receptor antagonist, in around 260 Japanese women experiencing vasomotor symptoms associated with menopause. The study is conducted by Astellas Pharma Inc. and is under Phase III clinical development.
Drug: NOE-115
Noema Pharma AG is conducting a Phase II multi-center clinical trial to investigate the preliminary efficacy, safety, and tolerability of vasomotor symptoms of menopause drug candidate NOE-115, a triple reuptake inhibitor, in women suffering from the condition. The study has enrolled around 24 patients and is expected to be completed by April 2025.
Reasons To Buy This Report
The Vasomotor Symptoms of Menopause Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for vasomotor symptoms of menopause. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into vasomotor symptoms of menopause collaborations, regulatory environments, and potential growth opportunities.
Key Questions Answered in the Vasomotor Symptoms of Menopause – Pipeline Insight Report
- Which companies/institutions are leading the vasomotor symptoms of menopause drug development?
- What is the efficacy and safety profile of vasomotor symptoms of menopause pipeline drugs?
- Which company is leading the vasomotor symptoms of menopause pipeline development activities?
- What is the current vasomotor symptoms of menopause commercial assessment?
- What are the opportunities and challenges present in the vasomotor symptoms of menopause drug pipeline landscape?
- What is the efficacy and safety profile of vasomotor symptoms of menopause pipeline drugs?
- Which company is conducting major trials for vasomotor symptoms of menopause drugs?
- Which companies/institutions are involved in vasomotor symptoms of menopause collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in vasomotor symptoms of menopause?
Global Vasomotor Symptoms Treatment Market
Global Clinical Trials Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Vasomotor Symptoms of Menopause
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Vasomotor Symptoms of Menopause
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Vasomotor Symptoms of Menopause: Epidemiology Snapshot
- 5.1 Vasomotor Symptoms of Menopause Incidence by Key Markets
- 5.2 Vasomotor Symptoms of Menopause – Patients Seeking Treatment in Key Markets
- 6 Vasomotor Symptoms of Menopause: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Vasomotor Symptoms of Menopause: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Vasomotor Symptoms of Menopause, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Vasomotor Symptoms of Menopause Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Vasomotor Symptoms of Menopause Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: Fezolinetant
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Other Drugs
- 11 Vasomotor Symptoms of Menopause Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: NOE-115
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: HS-10384
- 11.2.3 Other Drugs
- 12 Vasomotor Symptoms of Menopause Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug 1
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Other Drugs
- 13 Vasomotor Symptoms of Menopause Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Vasomotor Symptoms of Menopause, Key Drug Pipeline Companies
- 14.1 Noema Pharma AG
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Hansoh BioMedical R&D Company
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Astellas Pharma Inc.
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Bonafide Health
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Lindus Health
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
